Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Alpine Immune Sciences, Inc. < Previous 1 2 Next > Alpine Immune Sciences Announces Participation in the Bank of America Securities Healthcare Conference May 01, 2023 From Alpine Immune Sciences, Inc. Via Business Wire Tickers ALPN Alpine Immune Sciences Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results March 23, 2023 From Alpine Immune Sciences, Inc. Via Business Wire Tickers ALPN Alpine Immune Sciences to Present Povetacicept (ALPN-303) Phase 1 (RUBY-1) Study Data and Clinical Pharmacokinetic & Pharmacodynamic Modeling at Upcoming Scientific Conferences March 20, 2023 From Alpine Immune Sciences, Inc. Via Business Wire Tickers ALPN Alpine Immune Sciences to Present Povetacicept (ALPN-303) Phase 1 (RUBY-1) Study Data at the 2023 American Academy of Dermatology Annual Meeting March 16, 2023 From Alpine Immune Sciences, Inc. Via Business Wire Tickers ALPN Alpine Immune Sciences to Report Fourth Quarter and Full Year 2022 Financial Results March 15, 2023 From Alpine Immune Sciences, Inc. Via Business Wire Tickers ALPN Alpine Immune Sciences to Participate in Two Upcoming Healthcare Conferences February 28, 2023 From Alpine Immune Sciences, Inc. Via Business Wire Tickers ALPN Alpine Immune Sciences to Participate in the SVB Securities Global Biopharma Conference February 09, 2023 From Alpine Immune Sciences, Inc. Via Business Wire Tickers ALPN Alpine Immune Sciences Announces Participation in Fireside Chat at the 5th Annual Evercore ISI HealthCONx Conference November 22, 2022 From Alpine Immune Sciences, Inc. Via Business Wire Tickers ALPN Alpine Immune Sciences Provides Corporate Update and Reports Third Quarter 2022 Financial Results November 14, 2022 From Alpine Immune Sciences, Inc. Via Business Wire Tickers ALPN Alpine Immune Sciences to Report Third Quarter 2022 Financial Results November 07, 2022 From Alpine Immune Sciences, Inc. Via Business Wire Tickers ALPN Alpine Immune Sciences Presents Update Of ALPN-303 Phase 1 (RUBY-1) Clinical Data at the American Society of Nephrology Kidney Week 2022 Meeting November 03, 2022 From Alpine Immune Sciences, Inc. Via Business Wire Tickers ALPN Alpine Immune Sciences to Present ALPN-303 Phase 1 (RUBY-1) Study Data at 2022 American Society of Hematology Annual Meeting & Exposition November 03, 2022 From Alpine Immune Sciences, Inc. Via Business Wire Tickers ALPN Alpine Immune Sciences to Present ALPN-303 Phase 1 (RUBY-1) Study Data at Upcoming Scientific Conferences October 26, 2022 From Alpine Immune Sciences, Inc. Via Business Wire Tickers ALPN Alpine Immune Sciences Terminates Enrollment of Davoceticept Clinical Studies (NEON-1 and NEON-2) October 24, 2022 From Alpine Immune Sciences, Inc. Via Business Wire Tickers ALPN Alpine Immune Sciences Announces Pricing of $100 Million Public Offering September 20, 2022 From Alpine Immune Sciences, Inc. Via Business Wire Tickers ALPN Alpine Immune Sciences Announces Proposed Public Offering September 20, 2022 From Alpine Immune Sciences, Inc. Via Business Wire Tickers ALPN Alpine Immune Sciences to Highlight Clinical Updates on Autoimmune and Immuno-Oncology Programs at Inaugural R&D Day September 12, 2022 From Alpine Immune Sciences, Inc. Via Business Wire Tickers ALPN Alpine Immune Sciences Announces R&D Day to Provide Clinical Updates on Wholly-Owned Programs ALPN-303 and Davoceticept August 30, 2022 From Alpine Immune Sciences, Inc. Via Business Wire Tickers ALPN Alpine Immune Sciences Announces Inducement Grant to Andrew S. Sandler, M.D. Under Nasdaq Listing Rule 5635(c) August 18, 2022 From Alpine Immune Sciences, Inc. Via Business Wire Tickers ALPN Alpine Immune Sciences Provides Corporate Update and Reports Second Quarter 2022 Financial Results August 11, 2022 From Alpine Immune Sciences, Inc. Via Business Wire Tickers ALPN Alpine Immune Sciences Announces Participation in Fireside Chat at the 2022 Wedbush PacGrow Healthcare Virtual Conference August 04, 2022 From Alpine Immune Sciences, Inc. Via Business Wire Tickers ALPN Alpine Immune Sciences Appoints Andrew S. Sandler, M.D. as Chief Medical Officer June 07, 2022 From Alpine Immune Sciences, Inc. Via Business Wire Tickers ALPN Alpine Immune Sciences Announces Presentations at the 2022 EULAR and ASCO Annual Meetings May 26, 2022 From Alpine Immune Sciences, Inc. Via Business Wire Tickers ALPN Alpine Immune Sciences Announces FDA Removes Partial Clinical Hold on NEON-2 Clinical Trial of Davoceticept (ALPN-202) in Combination with Pembrolizumab May 24, 2022 From Alpine Immune Sciences, Inc. Via Business Wire Tickers ALPN Alpine Immune Sciences Provides Corporate Update and Reports First Quarter 2022 Financial Results May 12, 2022 From Alpine Immune Sciences, Inc. Via Business Wire Tickers ALPN Alpine Immune Sciences Announces Participation in May Investor Conferences May 03, 2022 From Alpine Immune Sciences, Inc. Via Business Wire Tickers ALPN Alpine Immune Sciences Publishes Key Preclinical Rationale for Davoceticept (ALPN-202), a First-in-Class CD28 Costimulator and Dual Checkpoint Inhibitor, in Nature Communications April 04, 2022 From Alpine Immune Sciences, Inc. Via Business Wire Tickers ALPN Alpine Immune Sciences to Host Virtual Investor Event at 2022 AACR Annual Meeting March 30, 2022 From Alpine Immune Sciences, Inc. Via Business Wire Tickers ALPN Alpine Immune Sciences Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results March 17, 2022 From Alpine Immune Sciences, Inc. Via Business Wire Tickers ALPN Alpine Immune Sciences Announces Participation in January Investor Conferences January 04, 2022 From Alpine Immune Sciences, Inc. Via Business Wire Tickers ALPN < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.